Skip to main navigation Skip to main content Skip to page footer
Menu

ΑΙΓΙΝΗΤΕΙΟ ΝΟΣΟΚΟΜΕΙΟ

ΔΕΛΗΓΙΑΝΝΗ ΧΡΙΣΤΙΝΑ

Christina Deligianni, MD, FEBN

E -mail: cdchristina@gmail.com

Tel: 0030 6974751646

Date of birth: 12/05/1983

Family status: Mother of two (2)

Appointments

Consultant, Neurology Department, Athens Naval Hospital, Athens, Greece (Dec 2018- present)

Commander, Hellenic Navy

Research and Clinical Fellow , 1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece

Member of European Headache Federation Board         (2021- now)

Member of Headache Panel of European Academy of Neurology

PhD candidate at National and Kapodistrian University of Athens, Athens, Greece

Professional Experience

2025: Co Chair Of 19th European Congress of Headache, Lisbon 4-6 Dec 2025

2018-now: Neurology Consultant, Athens Naval Hospital, Athens, Greece

2023-now: Research and Clinical Fellow, 1st Department of Neurology, Aiginiteion Hospital, Medical School, National and Kapodisrtian University of Athens, Athens, Greece 

2020-2022: Clinical and Research Fellowship, Danish Headache Center, University of Copenhagen, Glostrup Hospital, Denmark

28/06/2019: Awarded as a Fellow of the European Board of Neurology. 

28/01/2019: Authorized member of Hellenic Neurology Board. 

1/2012 – 4/2015 and 1/2018- 10/2018:  Resident in 1st Neurology Department, Aiginiteion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

01/2012 – 06/2012:  Resident in 1st Psychiatry Department, Aiginiteion Hospital, Medical School, National and Kapodisrtian University of Athens, Athens, Greece.

2010 – 2011: Resident in Internal Medicine, 1st Department of Internal Medicine, Athens Naval Hospital, Athens, Greece. 

2009 – 2010: Chief Sanitary Officer Supervision Warship Frigate "Elli", Greece.

2008 – 2009: Naval Hospital, Standard Practice Education as Sanitary Officer of the Navy: 13 Weeks Internal Medicine, Surgery 18 weeks and 5 weeks Laboratory Division.

Languages

English (B2 level), German (B1 level)

Education

2001-2007: Medical School, Aristotle’s University of Thessaloniki, Thessaloniki, Greece (Grade: Very well)

1998 - 2001: 3rd High School of Nea Filadelfia “Miltos Kountouras” (Greece). Grade: 19.3 /20.

 

Post-Graduate Seminars

  • Seminar-Certification Immediate Life Support (ILS), Center for Medical Education "Simuland", Athens, Greece.
  • Training seminar-certified Advanced Trauma Life Support (ATLS), Mediterraneo Hospital, Athens, Greece.
  • Training seminar-certification Naval Medicine, Naval Hospital, Athens, Greece.
  • Training seminar-diving-certification Hyperbaric Medicine, Naval Hospital, Athens, Greece.
  • Attendance of iHEAD seminar, International Headache Society (November 2014)

Publications - 

  1. Deligianni CI, Vikelis M, Mitsikostas DD. Depression in headaches: chronification. Curr Opin Neurol. 2012 Jun;25(3):277-83.
  2. Mitsikostas DD, Deligianni CI. Q- No: A Questionnaire to predict Nocebo in outpatients seeking neurological consultation. Neurol. Sci. 2015Mar; 36(3):379-81.
  3. Toutouzas K, Benetos G, Drakopoulou M, Deligianni CI, Spengos K, Stefanadis C, Siores E, Tousoulis D. Incremental Predictive value of carotid inflammation in acute ischemic stroke. Stroke 2015 Jan; 46(1):272-4.
  4. Lampl C, Rudolph M, Deligianni CI, Mitsikostas DD. Neck pain in episodic migraine: premonitory symptom or part of the attack? J Headache Pain. 2015;16:566.
  5. Mitsikostas DD, Ljubisavljevic S, Deligianni CI. Refractory burning mouth syndrome: clinical and practical evaluation comorbidities. Treatment and out and outcome. J Headache Pain. 2017 Dec;18(1):40.
  6. Mitsikostas DD, Belesioti I, Arvaniti C, Mitropoulou E, Deligianni C, Kasioti E, Constantinidis T, Dermitzakis M, Vikelis M; Hellenic Headache Society. Patients’ preferences for headache acute and preventive treatment. J Headache Pain. 2017 Oct 6;18(1):102.
  7. Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. Cephalalgia. 2021 Jun;41(7):851-864. doi: 10.1177/0333102421989601.
  8. Mavridis T, Deligianni CI, Karagiorgis G, Daponte A, Breza M, Mitsikostas DD. Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far? Pharmaceuticals (Basel). 2021 Jul 20;14(7):700. doi: 10.3390/ph14070700.
  9. Mavridis T, Breza M, Deligianni C, Mitsikostas DD. Current advances in the management of cluster headaches. Expert Opin Pharmacother. 2021 Oct;22(14):1931-1943. doi: 10.1080/14656566.2021.1924148.
  10. Mitsikostas DD, Aravantinou-Fatorou K, Deligianni C, Kravvariti E, Korompoki E, Mylona M, Vryttia P, Papagiannopoulou G, Delicha EM, Dellis A, Tsivgoulis G, Dimopoulos MA, Amanzio M, Sfikakis PP. Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. Vaccines (Basel). 2021 Oct 14;9(10):1179. doi: 10.3390/vaccines9101179.
  11. Constantinides VC, Deligianni C, Dimitrakopoulos A, Paraskevas GP, Kapaki E. Lentiform fork sign in a patient with systemic lupus erythematosus. Neurol Sci. 2021 Jan;42(1):349-352. doi: 10.1007/s10072-020-04607-y. Epub 2020 Jul 18.PMID: 32683567
  12. Deligianni CI, Mitsikostas DD, Ashina M. Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. Expert Opin Drug Saf. 2021 Aug;20(8):867-876. doi: 10.1080/14740338.2021.1933941.
  13. Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz D, Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z, Martelletti P, Ornello R, Raffaelli B, Boucherie DM, Pozo-Rosich P, Sanchez-Del-Rio M, Sinclair A, Maassen van den Brink A, Reuter U. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z.
  14. Sampatakakis SN, Lymperopoulos L, Mavridis T, Karagiorgis G, Papadopoulos C, Deligianni CI, Mitsikostas DD. Visual snow: A systematic review and a case series. Cephalalgia. 2022 Nov;42(13):1409-1419. doi: 10.1177/03331024221118917.
  15. Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-x. PMID: 35690723; PMCID: PMC9188162.
  16. Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M, Reuter U, Uluduz D, Versijpt J, Zeraatkar D, Sacco S. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023 May 19;24(1):56. doi: 10.1186/s10194-023-01594-1.
  17. Deligianni C, Martelletti P, Mitsikostas DD. Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome. J Comp Eff Res. 2023 Jul;12(7):e230082. doi: 10.57264/cer-2023-0082.
  18. Do TP, Deligianni C, Amirguliyev S, Snellman J, Lopez CL, Al-Karagholi MA, Guo S, Ashina M. Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans. Brain. 2023 Dec 1;146(12):5224-5234. doi: 10.1093/brain/awad261. PMID: 37540009; PMCID: PMC10690017.
  19. Rasmussen NB, Deligianni C, Christensen CE, Karlsson WK, Al-Khazali HM, Van de Casteele T, Granhall C, Amin FM, Ashina M. Correction: The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain. 2023 Jun 19;24(1):74. doi: 10.1186/s10194-023-01610-4. Erratum for: J Headache Pain. 2023 May 25;24(1):60.
  20. Rasmussen NB, Deligianni C, Christensen CE, Karlsson WK, Al-Khazali HM, Van de Casteele T, Granhall C, Amin FM, Ashina M. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain. 2023 May 25;24(1):60. doi: 10.1186/s10194-023-01599-w. Erratum in: J Headache Pain. 2023 Jun 19;24(1):74.
  21. Deligianni C, Pellesi L, Chaudhry BA, Haulund Vollesen AL, Snoer AH, Hannibal J, Jensen RH, Ashina M. Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study. Front Neurol. 2023 Apr 18;14:1135246. doi: 10.3389/fneur.2023.1135246.
  22. Deligianni CI, Sacco S, Ekizoglu E, Uluduz D, Gil-Gouveia R, MaassenVanDenBrink A, Ornello R, Sanchez-Del-Rio M, Reuter U, Versijpt J, de Vries T, Hussain M, Zeraatkar D, Lampl C. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine. J Headache Pain. 2023 Sep 19;24(1):128. doi: 10.1186/s10194-023-01657-3.
  23. Raffaelli B, García-Azorín D, Boucherie DM, Amin FM, Deligianni CI, Gil-Gouveia R, Kirsh S, Lampl C, Sacco S, Uluduz D, Versijpt J, MaassenVanDenBrink A, Zeraatkar D, Sanchez-Del-Rio M, Reuter U. European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate. J Headache Pain. 2023 Oct 10;24(1):134. doi:10.1186/s10194-023-01671-5.
  24. Lampl C, Versijpt J, Amin FM, Deligianni CI, Gil-Gouveia R, Jassal T, MaassenVanDenBrink A, Ornello R, Paungarttner J, Sanchez-Del-Rio M, Reuter U, Uluduz D, de Vries T, Zeraatkar D, Sacco S. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline. J Headache Pain. 2023 Apr 11;24(1):39. doi: 10.1186/s10194-023-01573-6. PMID: 37038134; PMCID: PMC10088191.
  25. Deligianni CI, Martelletti P, Mitsikostas DD. Placebo responses vary by route of administration in migraine prevention trials. What does this mean? J Med Econ. 2024 Jan-Dec;27(1):442-444. doi: 10.1080/13696998.2024.2323900. Epub 2024 Mar 12. PMID: 38425286.
  26. Mitsikostas DD, Caronna E, De Tommaso M, Deligianni CI, Ekizoglu E, Bolay H, Göbel CH, Kristoffersen ES, Lampl C, Moro E, Pozo-Rosich P, Sellner J, Terwindt G, Irimia-Sieira P. Headaches and facial pain attributed to SARS-CoV-2 infection and vaccination: a systematic review. Eur J Neurol. 2024 Jun;31(6):e16251. doi: 10.1111/ene.16251. Epub 2024 Feb 28. PMID: 38415282; PMCID: PMC11235838.
  27. Al-Khazali HM, Deligianni CI*, Pellesi L, Al-Karagholi MA, Ashina H, Chaudhry BA, Petersen AS, Jensen RH, Amin FM, Ashina M. Induction of cluster headache after opening of adenosine triphosphate-sensitive potassium channels: a randomized clinical trial. Pain. 2024 Jun 1;165(6):1289-1303. doi: 10.1097/j.pain.0000000000003130. Epub 2023 Dec 19. PMID: 38127692.*1st co author
  28. Mavridi A, Redmond A, Archontakis-Barakakis P, Bogdanova-Mihaylova P, Deligianni CI, Mitsikostas DD, Mavridis T. Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review. Toxins (Basel). 2024 Jun 28;16(7):295. Doi 10.3390/toxins16070295. PMID: 39057935; PMCID: PMC11281299.
  29. Mantonakis L, Belesioti I, Deligianni CI, Natsis V, Mitropoulou E, Kasioti E, Lypiridou M, Mitsikostas DD. Depression and Anxiety Symptoms in Headache Disorders: An Observational, Cross-Sectional Study. Neurol Int. 2024 Mar 18;16(2):356-369. doi: 10.3390/neurolint16020026. PMID: 38525706; PMCID: PMC10961742.
  30. Mitsikostas DD, Caronna E, De Tommaso M, Deligianni CI, Ekizoglu E, Bolay H, Göbel CH, Kristoffersen ES, Lampl C, Moro E, Pozo-Rosich P, Sellner J, Terwindt G, Irimia-Sieira P. Reply to the letter: Headaches during/after SARS-CoV-2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S. Eur J Neurol. 2024 Jul;31(7):e16308. doi: 10.1111/ene.16308. Epub 2024 Apr 16. PMID: 38628031.
  31. Versijpt J, Deligianni C, Hussain M, Amin F, Reuter U, Sanchez-Del-Rio M, Uluduz D, Boucherie D, Zeraatkar D, MaassenVanDenBrink A, Sacco S, Lampl C, Gil- Gouveia R. European Headache Federation (EHF) critical re-appraisal and meta- analysis of oral drugs in migraine prevention - part 4: propranolol. J Headache Pain. 2024 Jul 24;25(1):119. doi: 10.1186/s10194-024-01826-y. PMID: 39044170.
  32. Karagiorgis G, Christofilos S, Deligianni C, Spanou I, Vassilopoulou S, Mitsikostas DD. Galcanezumab add-on in refractory cluster headache. A case series. Pain Manag. 2024 Sep;14(9):491-495. doi: 10.1080/17581869.2024.2427564. Epub 2024 Nov 18. PMID: 39558673; PMCID: PMC11721606.
  33. Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM, Deligianni CI, Tomlinson A, Ashina H, Ruiz de la Torre E, Diener HC, Cipriani A, Ashina M. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta- analysis. BMJ. 2024 Sep 18;386:e080107. doi: 10.1136/bmj-2024-080107. PMID: 39293828; PMCID: PMC11409395.
  34. Christofilos SI, Mavridis T, Gkotzamanis V, Vasilopoulou S, Deligianni CI, Dimos-Dimitrios M. Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review. Pain Manag. 2025 Jul;15(7):425-439. doi: 10.1080/17581869.2025.2509474.
  35. Mitsikostas DD, Deligianni C, Mavridi A, Gkotzamanis V, Mavridis T. Steps to manage treatment- refractory migraine in adults. Expert Rev Neurother. 2025 Nov;25(11):1275-1289. doi: 10.1080/14737175.2025.2555305.
  36. Hoehne CL, Overeem LH, Sanchez-Del-Rio M, Deligianni C, Gil-Gouveia R, Versijpt J, Amin FM, Lampl C, Ryliskiene K, Tronvik E, Coppola G, Holland PR, MaassenVanDenBrink A, Martelletti P, Reuter U; European Headache Federation, EHF. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. J Headache Pain. 2026 Jan 3;27(1):10. doi: 10.1186/s10194-025-02256-0.
  37. BaniHani H, Lampl C, MaassenvandenBrink A, Amin FM, Carlsen LN, Coppola G, Deligianni C, Gil- Gouveia R, Holland PR, Husøy AK, Jensen R, Plácido M, Reuter U, Ryliškienė K, Sanchez Del Río M, Schytz HW, Tronvik E, Versijpt J, Steiner TJ. The role of community pharmacists in managing common headache disorders, and their integration within structured headache services: position statement on behalf of the European Headache Federation (EHF) and Lifting The Burden (LTB: the Global Campaign against Headache), with the formal endorsement of the International Pharmaceutical Federation. J Headache Pain. 2025 May 6;26(1):100. doi: 10.1186/s10194-025-02021-3. Erratum in: J Headache Pain. 2025 Jun 16;26(1):139. doi: 10.1186/s10194-025-02073-5.
  38. Mitsikostas DD, Deligianni C, Placebo and nocebo effects in headaches, Editor(s): Fabrizio Benedetti, Aziz Shaibani, Handbook of Clinical Neurology, Elsevier, Volume 213, 2025, Pages 175- 181, ISSN 0072-9752, ISBN 9780443298844, https://doi.org/10.1016/B978-0-443-29884- 4.00023-6.
  39. Braca S, Cretella G, Deligianni C, Kennelly L, Tseriotis VS, Andreou AP, Mitsikostas DD, Mavridis T. Noradrenergic system involvement as a major driver of tension-type headache: a systematic review of the current evidence. J Headache Pain. 2026 Jan 20. doi: 10.1186/s10194-026-02274-6.
  40. Hoehne CL, Overeem LH, Sanchez-Del-Rio M, Deligianni C, Gil-Gouveia R, Versijpt J, Amin FM, Lampl C, Ryliskiene K, Tronvik E, Coppola G, Holland PR, MaassenVanDenBrink A, Martelletti P, Reuter U; European Headache Federation, EHF. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. J Headache Pain. 2026 Jan 3;27(1):10. doi: 10.1186/s10194-025-02256-0.
  41.  De Loose L, Paemeleire K, Deligianni CI, Lampl C, Uluduz D, Tronvik E, Coppola G, Schytz H, Schoenen J, Del Rio MS, Martelletti P, Pozo-Rosich P, Gil-Gouveia R, Ryliskiene K, Sacco S, Ekizoglu E, Petrušić I, Fronczek R, Holland P, Reuter U, Goadsby PJ, MaassenVanDenBrink A, Versijpt J. What's a migraine day? Towards a consensus definition for clinical care and research - a Delphi panel-based study. J Headache Pain. 2026 May 9;27(1):135. doi: 10.1186/s10194-026-02383-2. Erratum in: J Headache Pain. 2026 May 28;27(1):149. doi: 10.1186/s10194-026-02407-x. PMID: 42106637; PMCID: PMC13169912.
  42. Braca S, Casillo F, Moreira S, Ekizoglu E, Bjork MH, Szewczyk AK, Van Dycke A, Uluduz D, Coppola G, Deligianni C, Lampl C, Tronvik E, Amin FM, Versijpt J, Ryliškienė K, Rio MSD, Holland PR, Terwindt G, Reuter U, MaassenVanDenBrink A, Gil-Gouveia R. Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF). J Headache Pain. 2026 Apr 17;27(1):120. doi: 10.1186/s10194-026-02350-x. PMID: 41998499; PMCID: PMC13126917.
  43. Deligianni C, Mitropoulou E, Kasioti E, Christofilos S, Karagiorgis G, Papageorgiou C, Vassilopoulou S, Sfikakis PP, Mitsikostas DD. Fear of death increases nocebo-prone behavior in people with headaches during covid-19. A longitudinal observational survey. Pain Manag. 2026 Sep 9:1-10. doi: 10.1080/17581869.2026.2726330. Epub ahead of print. PMID: 42712213.

 

Poster Presentations- Oral Presentations

 

  1. M.E. Evangelopoulos, E. Andreadou, C. Deligianni, G. Saltogiannis, I. Chasalevris, V. Chaina, C. Kilidireas. Follow-up of multiple sclerosis (MS) patients after natalizumab interruption. Clinical and MRIfindings. Switching to treatment with fingolimod. Neurol (2013) 260 (Suppl 1): S1–S280

     

  2. C Deligianni and DD Mitsikostas. Depression and anxiety symptoms in patients suffering from new daily persistent headache. A prospective, controlled study. The Journal of Headache and Pain 2014; 15 (Suppl 1): C15 (HMTI-0335). https://doi.org/10.1186/1129-2377-15-S1-C15

     

  3. C Deligianni and DD Mitsikostas.Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. The Journal of Headache and Pain; 15, 1; 1, 2015 The Journal of Headache and Pain 2014;15 (Suppl 1) :D14

https://doi.org/10.1186/1129-2377-15-S1-D14

  1. Mitsikostas DD, Deligianni CI. Treatment and outcome in medication overuse headache patients.  The Journal of Headache and Pain 2013; 14(Suppl 1):P180 

    http://www.thejournalofheadacheandpain.com/content/14/S1/P180.

  2. Mitsikostas DD, Belesioti , Arvaniti C, Mitropoulou E, Deligianni C,Kasioti E, Constantinidis T, Dermitzakis E, Vikelis M, and on behalf of the Hellenic Headache Society. Patients’ preferences for headache acute and preventive treatment. J Headache Pain. 2017; 18(1): 102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630539/

     

  3. E. Giallafos, E. Andreadou, E. Kosmas, V. Haina, M. Panagiotou, C. Deligianni, S. Kalantzi, M. Anagnostouli, K. Kilintireas, E. Stampoulis. Spatial QRS-T angle is increased in MS patients possibly due to ANS dysfunction. European Journal of Neurology 2014, 21 (Suppl. 1), 388–713 http://efns2014.efns.org/fileadmin/_migrated/content_uploads/Paper_Poster_Session_08_Multiple_sclerosis_and_related_disorders_1.pdf
  1. Mitsikostas DD, Belesioti Ι, Mitropoulou Ε, Deligianni C, Elina Kasioti, Konstantinidis T,  Dermitzakis E,  Vikelis E. PATIENTS PREFERENCES FOR HEADACHE TREATMENT (P1.205), Neurology April 18, 2017; 88 (16 Supplement) http://n.neurology.org/content/88/16_Supplement/P1.205
  1. Mitsikostas DD, Deligianni CI. Absolute and relative change in NEDA after treatmetn with oral disease modifying treatments in MS patients. (P4.387), Neurology April 18, 2017;  88 (16 Supplement) http://n.neurology.org/content/88/16_Supplement/P4.387.
  1. CI Deligianni, HM Al-Khazali, L Pellesi, M Al-Karagholi, H Ashina, BA Chaudhry, AS Petersen, RH Jensen, FM Amin, M Ashina. ATP-Sensitive Potassium Channel Activation Induces Cluster Headache Attack: A Randomized Clinical Trial. IHC 2023, Seoul.

 

ORAL PRESENTATIONS

C Deligianni, DD Mitsikostas.Q-No: A questionnaire to predict nocebo in outpatients seeking neurological consultation. EP 1235. EFNS-ENS, INSTABUL 2014

C Deligianni, DD Mitsikostas. Treatment and outcome in medication overuse headache patients.  EHMTIC 2012

CI Deligianni. Critical reappraisal of oral prophylactic treatment in migraine: Flunarizine. EHC, Vienna 2022.

CI Deligianni. Real World Data with Anti-CGRP(R) mAbs in Migraine. SAS School, Rotterdam Sep 2022.

CI Deligianni. EHF debate on acute migraine medications : Ditans., EHC 2023, Barcelona Dec 2023

CI Deligianni. Frequent episodic migraine vs chronic migraine; pathophysiological similarities and differences; impact on management. 1st National Headache Congress, Instabul, March 2024

CI Deligianni. Migraine Subtypes and their treatment. SAS School, Linz May 2024.

Χ. Δεληγιάννη. Φαρμακευτική Προφύλαξη Ημικρανίας: Μελλοντικές Θεραπείες . 15o Πανελλήνιο Συνέδριο ΕΕΚ, Αθήνα Μάρτιος 2024

Χ. Δεληγιάννη Δεδομένα πραγματικού κόσμου για τα Gepants και τα Ditans. 35ο Πανελλήνιο Συνέδριο ΕΝΕ, Ρόδος Μάιος 2024

Χ. Δεληγιάννη. Συστήματα νευρομεταβίβασης πόνου στην περιοχή της κεφαλής: PACAP . 16o Πανελλήνιο Συνέδριο ΕΕΚ, Βόλος,  Μάρτιος 2025

C. Deligianni. PACAP updates in migraine management. 4th Egyheadache, Cairo , June 2025

C. Deligianni. Anti CGRP mAbs in Migraine  Treatment. SAS School , Talinn October 2026

X. Δεληγιάννη. Debate 2. Νευροαπικόνιση σε όλους στις κεφαλαλγίες. ΚΑΤΑ. 17o Πανελλήνιο Συνέδριο ΕΕΚ, Ιωάννινα,  Μάρτιος 2026

C. Deligianni. CGRP-Targeted Therapies in Migraine. SAS School , Prague 21-22 May 2026

Χ. Δεληγιάννη. Τριδυμικές μονόπλευρες κεφαλαλγίες-υπάρχουν νέες θεραπείες, μπορούν αυτές να θεραπεύσουν και την πιθανή συνυπάρχουσα μανιοκατάθλιψη, 37ο Πανελλήνιο Συνέδριο ΕΝΕ, Καλαμάτα 2026

C. Deligianni Interactive Session on “Challenging headache cases: Interactive clinical problem-solving. Lecture title ”Refractory migraine: How to manage”,  12th EAN Congress 2026 27-30 June, Geneva

 

Chapters in Textbooks

DD Mitsikostas, CI Deligianni. Headache in systemic diseases. In: Case- based diagnosis and Management of Headache Disorders. Aksel Siva, Christian Lampl Edt. Springer, 2015, pp 229-234.

 

Deligianni CI, Mitsikostas DD. Nocebo in Headache treatment. In: Placebos and Nocebos in Headaches. DD Mitsikostas, F. Benedetti. Edt Springer, 2019, pp 75-84.

 

Deligianni C.I., Mavridis, T. (2026). Headache Attributed to Pheochromocytoma. In: Uludüz, D.,

Valença, M., Özge, A., Peres, M.F.P. (eds) Rare Causes of Headache Disorders. Headache. Springer,

Cham. https://doi.org/10.1007/978-3-032-10242-3_40

 

 

Educational Activities

Participated in educational workshops and seminars and courses related to headache: 

  • SAS( School of Advanced Studies)  Rotterdam 2023, Linz 2024, Talinn 2025, Prague 2026
  •   MSc Program in Clinical and Experimental Neurosurgery
·   Teaching fifth-year undergraduate medical students of European University of Cyprus; University of Nicosia

 

 

 

Congress and Conference Activities

 

Co- Chair of European Headache Congress , Lisbon 2025

 

Member of Scientific Program Committee of EHC (2021-today)

 

Grants- Scholarships

  1. International Headache Society Research Fellowship Grant Mar 2021-Feb 2022.
  2. Scholarship from Hellenic Neurological Society Sep 2020- Feb 2022
  3. Award from Hellenic Neurological Society for the published article from Greece with the highest IF (2012). 

ΝΕΥΡΟΛΟΓΙΚΗ: